Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Al-Ola Abdallah"'
Autor:
Monia Sigle, Siddhartha Ganguly, Shebli Atrash, Zahra Mahmoudjafari, Ghulam Rehman Mohyuddin, Joseph P. McGuirk, Al-Ola Abdallah, Hameem I Kawsar, Leyla Shune
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e212-e219
Background The number of therapeutic options for patients with relapsed/refractory multiple myeloma (RRMM) has increased significantly. Our institute treated a series of patients with RRMM using DPd (daratumumab, pomalidomide, dexamethasone) as salva
Autor:
Qing Zhang, Xenofon Papanikolaou, Al-Ola Abdallah, Shebli Atrash, Bart Barlogie, Caleb K. Stein
Publikováno v:
Journal of Global Oncology, Vol 4, Pp 1-8 (2017)
Journal of Global Oncology
Journal of Global Oncology
Purpose Multiple myeloma (MM) is a clonal bone marrow disease characterized by the neoplastic transformation of differentiated postgerminal B cells. It is a heterogeneous disease both at the genetic level and in terms of clinical outcome. Immunoglobu
Autor:
Saqib Abbasi, Brian McClune, Kellen Gil, Al-Ola Abdallah, Nausheen Ahmed, Leyla Shune, Joseph P. McGuirk, Ghulam Rehman Mohyuddin, Siddhartha Ganguly
Publikováno v:
Blood. 136:53-54
INTRODUCTION: With the advent of newer treatment options for patients with acute leukemia and myeloma, therapies are increasingly safely administered on an outpatient basis. We hypothesized increasing utilization of outpatient options would result in
Autor:
Ghulam Rehman Mohyuddin, Hameem I Kawsar, Monia Sigle, Al-Ola Abdallah, Leyla Shune, Zahra Mahmoudjafari, Joseph P. McGuirk, Atrash Shebli, Siddhartha Ganguly
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S303
Context: At this time, there is no rationale to favor a specific therapeutic class (e.g., immunomodulatory agents (IMiD), proteasome inhibitors (PI), or monoclonal antibody) over another for the treatment of relapsed/refractory myeloma (RRMM). Our in
Autor:
Al-Ola Abdallah, Angela Pennisi, Konstantinos Arnaoutakis, Paulette Mehta, Meghana Bansal, Issam Makhoul
Publikováno v:
Journal of Cancer Education. 31:736-741
Using the standardized ASCO Quality Oncology Practice Initiative (QOPI) guidelines for assessing quality cancer care, we identified communication about intent of chemotherapy as an area needing improvement in our program at the University of Arkansas
Autor:
Christoph Heuck, Sarah Waheed, Bart Barlogie, Alejandro Restrepo, Senu Apewokin, Al-Ola Abdallah, Shebli Atrash, Naveen Sanath Kumar, Donald J. Johann, Zainab Shahid, Muzaffar Jameel, Monica Grazziutti, Frits van Rhee, Saad Z. Usmani
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 14:211-214
Background Invasion of CNS in MM is an extremely rare occurrence that is associated with advanced disease with poor prognosis. Patients and Methods Our MM database identified 35 CNS MM cases presenting between January 1996 and March 2012. Descriptive
Autor:
Pooja Motwani, Arjun Swami, Varinder Kaur, Issam Makhoul, Shebli Atrash, Fade Mahmoud, Zhifu Xiang, Al-Ola Abdallah, Peter D. Emanuel, Daisy Alapat
Publikováno v:
Blood. 126:5019-5019
Background: Bing-Neel syndrome (BNS) or central nervous system (CNS) involvement in Waldenströms macroglobulinemia (WM) is rare and typically results from the infiltration of CNS by neoplastic lympho-plasmacytoid cells. The aim of this study is to p
Autor:
Bart Barlogie, Al-Ola Abdallah, Jameel Muzaffar, Sajjad Haider, Senu Apewokin, Nisar Ahmad, Alejandro Restrepo, Monica Grazziutti, Frits van Rhee, Saad Z. Usmani, Sarah Waheed, Zainab Shahid, Shebli Atrash
Publikováno v:
Blood. 120:2925-2925
Abstract 2925 Background: Multiple myeloma (MM) patients can present with neurologic manifestation either as part of the disease process or as a therapeutic complication, such as due to metabolic disorders such as hypercalcemia, uremia and hypervisco